nach oben

Drugs

Erschienen in:

01.04.2022 | AdisInsight Report

Gefapixant: First Approval

verfasst von: Anthony Markham

Erschienen in: Drugs | Ausgabe 6/2022

Einloggen, um Zugang zu erhalten

Abstract

Gefapixant (Lyfnua^®; Merck & Co.) is a first-in-class, non-narcotic, selective P2X3 receptor antagonist being developed for the treatment of refractory chronic cough or unexplained chronic cough. Marketing approval for gefapixant is being sought in the EU and USA, and the drug was recently approved for marketing in Japan as treatment for refractory or unexplained chronic cough. This article summarizes the milestones in the development of gefapixant leading to this first approval.

Nur mit Berechtigung zugänglich

Muccino D, Green S. Update on the clinical development of gefapixant, a P2X3 receptor antagonist for the treatment of refractory chronic cough. Pulm Pharmacol Ther. 2019;56:75–8.CrossRefPubMed

Kyorin. MSD K.K. receives manufacturing and marketing approval of LYFNUA^® tablets, world's first selective P2X3 receptor antagonist for the treatment of chronic cough [media release]. 20 Jan 2022. http://www.kyorin-pharm.com.

Merck AG. Merck Provides U.S. and Japan regulatory update for gefapixant [media release]. 24 Jan 2022. http://www.merck.com.

Ford AP, Dillon MP, Kitt MM, et al. The discovery and development of gefapixant. Auton Neurosci. 2021;235:102859.CrossRefPubMed

Martinez FJ, Afzal AS, Smith JA, et al. Treatment of persistent cough in subjects with idiopathic pulmonary fibrosis (IPF) with gefapixant, a P2X3 antagonist, in a randomized, placebo-controlled clinical trial. Pulm Ther. 2021;7(2):471–86.CrossRefPubMedPubMedCentral

Roche. Roche licenses first-in-class treatments for chronic pain to afferent pharmaceuticals; afferent secures $23 million in series A financing [media release]. 17 Dec 2009. http://www.roche.com.

Merck Co. Merck announces second-quarter 2016 financial results [media release]. 29 Jul 2016. http://www.merck.com.

Kyorin. MSD and KYORIN conclude distribution agreement of gefapixant citrate, a treatment for chronic cough, in Japan [media release]. 26 Apr 2021. http://www.kyorin-pharm.com.

Richards D, Gever JR, Ford AP, et al. Action of MK-7264 (gefapixant) at human P2X3 and P2X2/3 receptors and in vivo efficacy in models of sensitisation. Br J Pharmacol. 2019;176(13):2279–91.PubMedPubMedCentral

10.

MSD. Lyfnua^® tablets 45 mg [Japanese prescribing information]. 2022. https://www.pmda.go.jp/PmdaSearch/iyakuDetail/ResultDataSetPDF/170050_22900A0F1027_1_02. Accessed 7 Mar 2022.

11.

Nussbaum JC, Hussain A, Ma B, et al. Characterization of the absorption, metabolism, excretion, and mass balance of gefapixant in humans. Pharmacol Res Perspect. 2022;10(1):e00924.CrossRefPubMedPubMedCentral

12.

McCrea JB, Hussain A, Ma B, et al. Assessment of pharmacokinetic interaction between gefapixant (MK-7264), a P2X3 receptor antagonist, and the OATP1B1 drug transporter substrate pitavastatin. Clin Pharmacol Drug Dev. 2021;11:406–12. https://doi.org/10.1002/cpdd.1047.CrossRefPubMed

13.

Nussbaum JC, Hussain A, Ma B, et al. Assessment of the effect of pyrimethamine, a potent inhibitor of multidrug and toxin extrusion protein 1/2K, on the pharmacokinetics of gefapixant (MK-7264), a P2X3 receptor antagonist. Clin Pharmacol Drug Deliv. 2022;11(1):123–8.CrossRef

14.

McGarvey L, Birring S, Morice A, et al. Efficacy and safety of gefapixant, a P2X3 receptor antagonist, in refractory chronic cough and unexplained chronic cough (COUGH-1 and COUGH-2): results from two double-blind, randomised, parallel-group, placebo-controlled, phase 3 trials. Lancet. 2022. https://doi.org/10.1016/S0140-6736(21)02348-5.CrossRefPubMed

15.

Dicpinigaitis P, Birring SS, Morice A, et al. Patient-reported chronic cough severity over 52 weeks in two phase 3 trials of gefapixant. Eur Respir J. 2021;58(suppl 65):OA1588.

16.

Smith JA, Kitt MM, Morice AH, et al. Gefapixant, a P2X3 receptor antagonist, for the treatment of refractory or unexplained chronic cough: a randomised, double-blind, controlled, parallel-group, phase 2b trial. Lancet Respir Med. 2020;8(8):775–85.CrossRefPubMed

17.

Smith JA, Kitt MM, Butera P, et al. Gefapixant in two randomised dose-escalation studies in chronic cough. Eur Respir J. 2020;55(3):1901615. https://doi.org/10.1183/13993003.01615-2019.CrossRef

18.

Birring S, Cardozo L, Dmochowski R, et al. A phase 3b trial evaluating the efficacy of gefapixant in reducing stress urinary incontinence in women with chronic cough. Am J Respir Crit Care Med Conf Am Thorac Soc Int Conf ATS. 2020;201(1):A7776.

Titel: Gefapixant: First Approval
verfasst von: Anthony Markham
Publikationsdatum: 01.04.2022
Verlag: Springer International Publishing
Erschienen in: Drugs / Ausgabe 6/2022
Print ISSN: 0012-6667
Elektronische ISSN: 1179-1950
DOI: https://doi.org/10.1007/s40265-022-01700-8

Die Highlights vom Kongress des American College of Cardiology 2024

Springer Medizin

Gefapixant: First Approval

Abstract

Die Highlights vom Kongress des American College of Cardiology 2024

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 6/2022

Tebentafusp: First Approval

Benefits and Harms of ‘Smart Drugs’ (Nootropics) in Healthy Individuals

Clazosentan: First Approval

Daratumumab: A Review in Newly Diagnosed Systemic Light Chain Amyloidosis

BCMA-Targeted Biologic Therapies: The Next Standard of Care in Multiple Myeloma Therapy

Palovarotene: First Approval